Vanguard Total International Stock ETF
Most Recent
Why Investors Should Monitor Geopolitical Risks
Localized geopolitical risks like the tension in the Middle East are unlikely to cause substantial damage to the markets in the long run, though they could bolster oil prices in the short term.
A Deeper Look at Valeant Pharmaceuticals’ Recent Financial Performance
In 3Q16, Valeant Pharmaceuticals (VRX) generated revenues of $2.4 billion, compared with $2.2 billion in 3Q17.
What’s behind the Stock Market Fall?
A fall of more than 10% in market value from the most recent peak is generally considered to be a correction. The US indexes have had four such corrections since the onset of the current bull market cycle in 2009.
Analysts’ Recommendations for Novartis after Its 4Q17 Earnings
Novartis (NVS) is expected to report earnings per share of $1.26 in 1Q18 compared to EPS of $1.13 in 1Q17.
GlaxoSmithKline Projects Tough Environment for Triumeq and Tivicay
In 3Q17, dolutegravir franchise drugs Triumeq and Tivicay were major drivers of GlaxoSmithKline’s (GSK) rising HIV portfolio revenues.
What Analysts Recommend for GlaxoSmithKline in January 2018
Of the 31 analysts covering GlaxoSmithKline in January 2018, five have recommended a “strong buy,” seven have recommended a “buy,” 15 have recommended a “hold,” three have recommended a “sell,” and only one has recommended a “strong sell.”
How Is Novartis’s Kymriah Positioned for 2018?
FDA and EC approvals for label expansion are expected to further boost Kymriah’s sales growth.
Teva Pharmaceutical: Still Focused on New Product Launches
With the acquisition of Actavis, Teva has a combination of the biggest first-to-file generics and biosimilars portfolio in the United States.
How Teva Pharmaceutical Plans to Improve Financial Profile
Teva Pharmaceutical has implemented a clear strategy to improve its financial profile and establish long-term growth prospects.
A Look at AstraZeneca’s Iressa, Zoladex, Casodex, and Arimidex
In 3Q17, AstraZeneca’s (AZN) Iressa generated revenues of $137.0 million, which reflected ~10.0% growth on a year-over-year basis.
Behind Novartis’s Entresto and Gilenya Performances in 3Q17
In 3Q17, Novartis’s (NVS) Entresto generated revenues of $128 million, compared with $53 million in 3Q16. Entresto witnessed a ~16% rise on a QoQ basis.
How Novartis’s Immunology and Dermatology Portfolio Looks after 3Q17
In 3Q17, Novartis’s (NVS) Neoral generated revenues of ~$126 million, which represents a ~3% YoY (year-over-year) fall and a 2% QoQ fall.
Siliq Could Strengthen Valeant’s Dermatology Franchise
In October 2017, Valeant Pharmaceuticals presented the results of its pivotal Phase 3 long-term extension AMAGINE-2 trial with Siliq.
Could Tecentriq Be Roche’s Long-Term Growth Driver?
In July 2017, the EC’s CHMP recommended a positive opinion for Roche’s (RHHBY) Tecentriq as a monotherapy for the treatment of adults with metastatic NSCLC previously treated with chemotherapy.
How Are Novartis’s Blockbuster Drugs Gleevec and Tasigna Positioned?
In 1H17, Novartis’s (NVS) Gleevec reported revenues of around $1.1 billion, which reflected a ~39% decline on a year-over-year (or YoY) basis.
GlaxoSmithKline’s Consumer Healthcare Business Improved
GlaxoSmithKline (GSK) added new products and improved the supply chain for consumer healthcare products in the last few years.
Canadian Pacific Railway’s Freight Traffic Was a Mixed Bag in Week 32
Canadian Pacific Railway (CP) is the second largest freight rail in Canada.
EMEA and APAC: Fresenius Medical Care’s Dialysis Products Business
In 1H17, Fresenius Medical Care (FMS) earned ~1.6 billion euros from the sale of dialysis products, which equals year-over-year growth of 8% on a reported basis.
What Led to Canadian Pacific Railway’s Volume Rise in Week 30?
CP hauled slightly more than 30,000 railcars in the 30th week compared with over 29,000 railcars in the 30th week last year.
Tagrisso Expected to Be a Key Growth Driver for AstraZeneca in 2017
Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.
AstraZeneca’s New Oncology Portfolio May See Healthy Growth
In 1Q17, AstraZeneca’s (AZN) new oncology portfolio reported global sales of around $236.0 million. Tagrisso earned revenues of $171.0 million globally.
Examining the 1Q17 Performance of AZN’s Respiratory Segment
AstraZeneca’s (AZN) Respiratory segment is one its key growth platforms. The segment reported nearly flat revenue of $1.2 billion at constant exchange rates in 1Q17.
Will There Be an Economic Slowdown in 2017?
Any slowdown in China’s economic growth is expected to impact developed (SPY) (EWU) (HEDJ) and emerging economies (FXI) (EEM).
Novartis Focuses on Portfolio Prioritization to Boost Profitability
To ensure long-term relevance as well as quick adaptability to changing market needs, Novartis (NVS) is focusing on five major initiatives in 2017.
Novartis Has Revamped Its Commercial Strategy for 2017
Besides focusing on research and development (or R&D) efforts, Novartis (NVS) is also aiming to revamp its commercial strategy in 2017.
Does Novartis See Much Potential for Its Surgical Business?
In 2017, Novartis (NVS) has planned to conduct a review of its Alcon segment to evaluate the business’s growth potential.
How Novartis Is Aiming to Increase Entresto Sales in 2017
In 2017, Novartis (NVS) expects its heart failure drug, Entresto, to earn revenues in excess of $500 million.
What Analysts Recommend for Novartis in 2017
In 2016, Novartis (NVS) reported revenues of $48.4 billion, a flat year-over-year (or YoY) performance on a constant currency basis.
Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017
On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).
AstraZeneca’s Symbicort: Dominant Player in Inhaler Segment
In 2016, AstraZeneca’s (AZN) Symbicort reported revenues close to $3.0 billion, which is a YoY fall of about 10.0% on a CER basis.
Changes in AstraZeneca’s Valuation in Fiscal 2016
AstraZeneca (AZN) reported an ~5% decline in its fiscal 2016 revenues at constant exchange rates. It reported revenues of $23.0 billion, compared to ~$23.6 billion in fiscal 2015.
What Impact Did the Brexit Vote Have on the UK and Global Growth?
In an interview with Wall Street Week on February 10, 2017, Bob Diamond spoke about the impact of Brexit on global growth and the European markets.
GlaxoSmithKline’s Revenue Trend for 4Q16
On February 8, 2017, GlaxoSmithKline (GSK) reported its 4Q16 earnings. Revenues rose 21.0% to 7.6 billion pounds, and EPS was 26 pence.
Fiscal and Trade Policies to Work Closely for Economic Growth
The Trump administration’s protectionist policy decisions are expected to affect global trade.
AstraZeneca’s Tagrisso Had a Strong Commercial Launch in 2016
After its commercial launch in 41 countries, AstraZeneca’s Tagrisso has witnessed a solid uptake, earning revenues of $276.0 million in 2016 YTD.
How Brexit Could Impact GDP, Capital Flows, and Growth in the UK
According to the International Monetary Fund’s World Economic Outlook Database, the UK’s GDP was $2.7 trillion in 2015.
Bill Gross: Possibility of Deglobalization in the Economy
Gross warned about deglobalization in the global economy. Trade between nations, exacerbating immigration issues, and stagnant economic growth formed his belief.
Bill Gross: What’s His New Normal Thesis?
Recently, Gross has been repeatedly mentioning a “new normal” that the developed world seems to be in. Real GDP growth is around 2% in the US.
Why Investors Shouldn’t Be Panicked about Brexit
All the global markets recovered impressively after their two-day falls as a result of the Brexit results.
George Soros: Brexit May Spark Disintegration in the European Union
With the Brexit vote, the European Union’s disintegration has already begun. The pound is already at historic lows against the US dollar (UUP).
Everything Is Being Repriced after the Brexit Vote, Says Marc Lasry
The Brexit referendum results are already playing havoc with the European and other world capital markets.
Investors Shift Their Focus to the UK—What Lies Ahead?
In this series, we’ll look at some asset managers’ perspectives on the Brexit vote and its effect on the Market. We’ll identify factors that could lead to similar votes, and we’ll discuss what lies ahead for the UK.
China’s Unleashing a Massive Stimulus to Boost the Economy
China’s (FXI) (MCHI) government initiated various stimulus measures to arrest the slowing growth. Currently, the bank lending rate is at a record low.
Why China Could Surprise Markets to the Upside
The massive financial stimulus package unleashed in China (MCHI) appears to be supporting economic growth in 2016 and 2017.
Dry Bulk Shipping Industry: Performance in 2015
Dry bulk shipping got a major boost from China’s increased appetite for iron ore and coal almost eight years ago. Large ship orders are driving the current oversupply.
Financials Must-know: Why junk bond spreads react to market momentum
High yield debt mutual funds recorded a net inflow of $1.7 billion in the week ending October 24.
Financials Why some unconstrained bond funds are seeing investor outflows
Legendary bond investor Bill Gross left Pacific Investment Management Co. (or PIMCO) in September, causing investors to exit en masse from PIMCO-sponsored funds. Total outflows for all of PIMCO’s funds were estimated at $23.5 billion in September.